

Supplementary Table SI. Definitions of statin intolerance. Based on [11–15]

<p>EAS (2015)</p>	<p>Assessment of SAMS in the context of:</p> <ul style="list-style-type: none"> • the character of muscle symptoms • the presence or absence of CK elevations, categorized as: <ul style="list-style-type: none"> - CK < ULN, < 4x ULN, < 10x ULN, > 10x ULN, or > 40x ULN • temporal association with statin initiation, dechallenge, and rechallenge
<p>ILEP (2015)</p>	<ul style="list-style-type: none"> • inability to tolerate ≥ 2 statins, including: <ul style="list-style-type: none"> - one at the lowest dose - the other at any dose • intolerable side effects or significant biomarker elevations, which: <ul style="list-style-type: none"> - improve or resolve after dose reduction or statin discontinuation - are not associated with predispositions or recognized risk factors
<p>CCWG (2016)</p>	<ul style="list-style-type: none"> • inability to tolerate ≥ 2 statins, including: <ul style="list-style-type: none"> - atorvastatin - rosuvastatin • significant symptoms and/or biomarker abnormalities, which: <ul style="list-style-type: none"> - are related to statin challenge-dechallenge-rechallenge - are not associated with drug-drug interactions or untreated risk factors - preclude long-term statin use, adherence, and therapeutic goal attainment
<p>LLAC (2017)</p>	<ul style="list-style-type: none"> • inability to tolerate: <ul style="list-style-type: none"> - ≥ 2 statins at any dose, OR - doses higher than rosuvastatin 5 mg, atorvastatin 10 mg, simvastatin 20 mg, pravastatin 20 mg, lovastatin 20 mg, fluvastatin 40 mg, or pitavastatin 2 mg, due to symptoms or CK changes not associated with drug-drug interactions or recognized risk factors • intolerable symptoms or severe myopathy, which: <ul style="list-style-type: none"> - occur within 12 weeks of statin initiation, dose increase, or administration of a drug metabolized through the same pathway - improve or resolve within 2–4 weeks after statin discontinuation - worsen in up to 4 weeks after rechallenge
<p>NLA (2022)</p>	<ul style="list-style-type: none"> • inability to tolerate ≥ 2 statins, including: <ul style="list-style-type: none"> - ≥ 1 at the lowest dose • ≥ 1 side effect, which: <ul style="list-style-type: none"> - improves or resolves after dose reduction or statin discontinuation • complete intolerance: <ul style="list-style-type: none"> - inability to tolerate any statin dose • partial statin intolerance: <ul style="list-style-type: none"> - inability to tolerate the statin dose required to reach the therapeutic goal

CCWG – Canadian Consensus Working Group, CK – creatine kinase, EAS – European Atherosclerosis Society, ILEP – International Lipid Expert Panel, LLAC – Luso-Latin American Consortium, NLA – National Lipid Association, SAMS – statin-associated muscle symptoms, ULN – upper limit of normal.